Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Chronic myelomonocytic leukemia

Chronic myelomonocytic leukemia

Part of Leukemia

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Chronic myelomonocytic leukemia

61 trials tracked for Chronic myelomonocytic leukemia: 5 in phase 3 or 4 and 2 with published results. The most-cited published study has 130 citations.

61Trials tracked
5Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 5 Phase 2 43 Phase 1 6 Other / NA 7
  1. Phase 3 Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Completed · 130 cited
  2. Phase 3 Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML Completed · 89 cited
  3. Phase 3 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed
  4. Phase 3 Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Completed
  5. Phase 3 Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML Completed
  6. Phase 2 Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation Completed
Show 44 more trials
  1. Phase 2 Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Completed
  2. Phase 2 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Completed
  3. Phase 2 Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia Completed
  4. Phase 2 Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Completed
  5. Phase 2 An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) Completed
  6. Phase 2 Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS Completed
  7. Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  8. Phase 2 Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia Completed
  9. Phase 2 Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Completed
  10. Phase 2 A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). Completed
  11. Phase 2 Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms Completed
  12. Phase 2 Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
  13. Phase 2 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed
  14. Phase 2 Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies Completed
  15. Phase 2 MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia Completed
  16. Phase 2 Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant Completed
  17. Phase 2 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia Completed
  18. Phase 2 Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome Completed
  19. Phase 2 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed
  20. Phase 2 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed
  21. Phase 2 Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Completed
  22. Phase 2 Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Completed
  23. Phase 2 Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant Completed
  24. Phase 2 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed
  25. Phase 2 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  26. Phase 2 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Completed
  27. Phase 2 Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm Completed
  28. Phase 2 Oral Clofarabine Study in Patients With Myelodysplastic Syndrome Completed
  29. Phase 2 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies Completed
  30. Phase 2 Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia Completed
  31. Phase 2 Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) Completed
  32. Phase 2 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed
  33. Phase 2 Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Completed
  34. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed
  35. Phase 2 WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed
  36. Phase 2 Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders Completed
  37. Phase 2 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Completed
  38. Phase 2 Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  39. Phase 2 Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome Completed
  40. Phase 2 A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia Completed
  41. Phase 2 Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) Completed
  42. Phase 2 Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) Completed
  43. Phase 1 Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS Completed
  44. Phase 1 A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients Completed

Showing the 50 most-cited and recently-updated of 61 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Chronic myelomonocytic leukemia: what the trials found

Fludarabine has been evaluated in multiple clinical trials for the treatment of chronic myelomonocytic leukemia (CMML) [1, 10, 20]. In one study involving a cohort with varying tacrolimus prophylaxis durations, 33% to 42% of participants were able to discontinue prophylactic tacrolimus, with only one instance of Grade III-IV acute GVHD reported in the 90-day cohort 20.

Azacitidine has been investigated across several trials for CMML [12, 14, 19]. In a large Phase 3 trial (N=454), Azacitidine did not show statistically significant differences in Event-Free Survival (p=0.557), Overall Survival (p=0.152), or Time to AML Transformation (p=0.562) compared to the control group 3.

Guadecitabine was evaluated in a Phase 3 trial (N=417); while it did not show statistically significant differences in Overall Survival (p=0.6063), results were reported for transfusion independence and marrow complete response rates 6. Other established interventions include Glasdegib 5 and ASTX727, the latter of which was evaluated regarding LINE-1 demethylation percentages and Grade 3 or higher treatment-emergent adverse events in MDS/CMML patients 4.

A supersaturated calcium phosphate rinse was shown to maintain a consistent duration of severe oral mucositis (WHO Grade 3 or 4) at 4.5 for the study population 7.

Recent results — preliminary, needs further review

  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401 was evaluated in a Phase 1 trial (N=8) 2.
  • Fludarabine phosphate was investigated in a Phase 2 trial (N=62) 9.
  • Donor Lymphocytes were evaluated in a Phase 2 trial (N=55) 8.

For the clinician treating this condition

  • Fludarabine is established as an intervention for CMML, with data available regarding its use alongside tacrolimus prophylaxis [1, 10, 20].
  • Azacitidine has been tested in large-scale trials; however, significant improvements in EFS, OS, or time to AML transformation were not observed in the primary Phase 3 study reported [3, 12, 14, 19].
  • Guadecitabine showed no statistically significant difference in Overall Survival compared to control groups in a large trial 6.

AI synthesis of 9 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report and review: azacytidine plus ruxolitinib in connective tissue disease with CMML and myelofibrosis
Allergy & Immunology Sys. Review
Case report and review: azacytidine plus ruxolitinib in connective tissue disease with CMML and myelofibrosis A single patient found relief from blood cancer with a new drug combo
This case report and literature review describes a 52-year-old male with connective tissue disease, chronic myelomonocytic leukemia, and mye…
One man with blood cancer saw his fever and anemia improve after two years on a specific drug mix, offering a glimpse into potential new tre…
Frontiers May 14, 2026
Decitabine versus hydroxyurea in advanced chronic myelomonocytic leukemia shows survival differences linked to baseline counts
Oncology RCT
Decitabine versus hydroxyurea in advanced chronic myelomonocytic leukemia shows survival differences linked to baseline counts Keeping Blood Cell Counts Low in Leukemia Predicts Who Lives Longer
This randomized controlled trial (RCT) enrolled 120 patients with advanced proliferative chronic myelomonocytic leukemia (CMML) comparing de…
In chronic myelomonacytic leukemia, keeping abnormal blood cells low after treatment predicts who lives longer than bone marrow changes alon…
Apr 18, 2026
Case report: CMML initially diagnosed as ITP in one patient, stabilized with decitabine
Hematology
Case report: CMML initially diagnosed as ITP in one patient, stabilized with decitabine A single case shows leukemia can initially look like a different blood disorder
A case report describes one patient initially diagnosed with immune thrombocytopenia (ITP) who was later found to have chronic myelomonocyti…
A single case shows leukemia can initially look like a different blood disorder, so doctors must watch for hidden mutations when standard tr…
Frontiers Apr 1, 2026

Research across Leukemia

Related studies from across the Leukemia family.

MRG mutations correlate with worse overall survival and lower remission in NPM1-mutated AML
Hematology Meta-analysis
MRG mutations correlate with worse overall survival and lower remission in NPM1-mutated AML Specific gene mutations linked to worse outcomes in certain leukemia
This meta-analysis of 4,363 patients found that MRG mutations (such as ASXL1, BCOR, and EZH2) are associated with inferior overall survival …
New data shows that specific gene mutations can predict poorer survival and lower remission rates for patients with a specific type of leuke…
Sep 1, 2026
Treosulfan-fludarabine improves 24-month event-free survival to 65% versus 53% in AML patients
Hematology RCT
Treosulfan-fludarabine improves 24-month event-free survival to 65% versus 53% in AML patients Treosulfan Shows Better Outcomes for Patients with Acute Myeloid Leukemia
This Phase 3 randomized trial subgroup analysis of 352 patients with AML undergoing alloHCT found treosulfan-fludarabine superior to reduced…
A new analysis of a Phase 3 trial suggests treosulfan may offer better survival rates and fewer complications for patients with acute myeloi…
Sep 1, 2026
Dasatinib 50 mg maintains efficacy while reducing pleural effusion and thrombocytopenia in CP-CML
Hematology Meta-analysis
Dasatinib 50 mg maintains efficacy while reducing pleural effusion and thrombocytopenia in CP-CML Lower Dasatinib Dose May Improve Tolerability for Leukemia Patients
This meta-analysis of 7 nonoverlapping reports compared dasatinib 50 mg and 100 mg in adults with chronic-phase chronic myeloid leukemia. Th…
A lower daily dose of dasatinib may offer similar effectiveness with fewer side effects for adults with chronic-phase chronic myeloid leukem…
Sep 1, 2026
Clinically significant CMV infection occurs in 9% of patients receiving bispecific antibodies for hematologic malignancies
Hematology Meta-analysis
Clinically significant CMV infection occurs in 9% of patients receiving bispecific antibodies for hematologic malignancies Bispecific Antibodies Linked to Lower Rates of CMV Infection
This meta-analysis of 23 studies and a single-center cohort evaluated bispecific antibody use in multiple myeloma, B-cell lymphoma, and acut…
New data shows that patients receiving bispecific antibodies for certain blood cancers may have lower rates of serious CMV infections.
Frontiers Aug 27, 2026
6-month IS value predicts MR4.5 attainment and TKI discontinuation eligibility in CML patients
Hematology Phase III
6-month IS value predicts MR4.5 attainment and TKI discontinuation eligibility in CML patients Trial Shows Early Markers Predict Success in Chronic Myeloid Leukemia
This observational study of 431 patients with chronic myeloid leukemia (CML) on second-generation TKIs found that the 6-month IS value is a …
New data from a Phase 3 trial shows that early markers can help predict which patients with chronic myeloid leukemia may reach specific trea…
Aug 25, 2026
Pirtobrutinib Combined with Venetoclax and Rituximab Improves Progression Free Survival
Oncology RCT
Pirtobrutinib Combined with Venetoclax and Rituximab Improves Progression Free Survival Trial shows pirtobrutinib improves survival for chronic lymphocytic leukemia
Adding pirtobrutinib to a venetoclax-rituximab regimen significantly extends progression-free survival in patients with chronic lymphocytic …
A new combination treatment involving pirtobrutinib may help patients with chronic lymphocytic leukemia live longer without their cancer pro…
Aug 9, 2026
Deep learning for leukemia diagnosis faces fragmented research and limited multimodal integration in current literature
Hematology Sys. Review
Deep learning for leukemia diagnosis faces fragmented research and limited multimodal integration in current literature AI for leukemia diagnosis still fragmented, review finds
This scoping review evaluates deep learning techniques for leukemia detection across morphological, immunophenotyping, and molecular modalit…
A new review shows AI tools for leukemia diagnosis are promising but fragmented, with few using multiple data types.
Frontiers Aug 8, 2026
Leukapheresis not clearly linked to lower 30-day mortality in AML with hyperleukocytosis
Hematology Meta-analysis
Leukapheresis not clearly linked to lower 30-day mortality in AML with hyperleukocytosis Leukapheresis Shows No Clear Early Death Benefit in AML
This meta-analysis of 1406 adults with AML and hyperleukocytosis found that leukapheresis was not clearly associated with lower 30-day morta…
A review of 1406 AML patients found leukapheresis did not clearly lower 30-day death risk. Evidence is weak.
Aug 3, 2026
AML infiltration of bile duct identified as primary cause of acute pancreatitis in case report
Rheumatology Sys. Review
AML infiltration of bile duct identified as primary cause of acute pancreatitis in case report Leukemia Cells Found as Cause of Severe Pancreatitis
This case report and literature review describes a 34-year-old man with acute pancreatitis and type 2 diabetes, where acute myeloid leukemia…
A rare case shows how a specific type of leukemia can infiltrate the pancreas and cause severe inflammation in patients with diabetes.
Frontiers Aug 3, 2026
IV-PEG asparaginase compared to IM-EC in children with acute lymphoblastic leukemia
Hematology Phase III
IV-PEG asparaginase compared to IM-EC in children with acute lymphoblastic leukemia PEG-asparaginase shows lower toxicity in childhood leukemia trial
This Phase 3 randomized controlled trial evaluated intravenous PEG-asparaginase (IV-PEG) versus intramuscular native E. coli L-asparaginase …
A new trial finds that PEG-asparaginase may cause fewer side effects than standard treatment for children with leukemia.
CT.gov Jul 30, 2026
TKI plus chemotherapy achieves deep molecular remission in Ph+ leukemia case with diagnostic framework
Allergy & Immunology Meta-analysis
TKI plus chemotherapy achieves deep molecular remission in Ph+ leukemia case with diagnostic framework One patient's leukemia remission offers clues for rare diagnosis
This systematic review with a case report describes a patient with Philadelphia chromosome-positive leukemia who achieved complete remission…
A patient with a rare leukemia achieved deep remission for 35 months. The case highlights how to tell apart two similar-looking blood cancer…
Frontiers Jul 29, 2026
Imatinib achieves complete cytogenetic response in a pediatric patient with suspected chronic myeloid leukemia
Pediatrics Sys. Review
Imatinib achieves complete cytogenetic response in a pediatric patient with suspected chronic myeloid leukemia Imatinib works for CML in child with high platelets
This case report describes a pediatric patient with isolated thrombocytosis who achieved a complete cytogenetic response to imatinib after f…
A child with high platelets and no response to standard therapy was found to have CML and responded to imatinib.
Frontiers Jul 21, 2026

Questions about Chronic myelomonocytic leukemia

Can ruxolitinib help CMML patients who also have connective tissue disease?

A specific case report shows that combining azacytidine with ruxolitinib helped a patient with connective tissue disease, CMML, and myelofibrosis by reducing fever, correcting high monocyte counts, and improving anemia.

Full answer →
What happens if a CMML patient is first diagnosed with ITP?

CMML can be misdiagnosed as ITP when thrombocytopenia is the first symptom; immunosuppressive therapy may temporarily raise platelets, but the underlying CMML progresses. Decitabine can stabilize the condition.

Full answer →